脂质体两性霉素B (AmBisome)在地中海内脏利什曼病:一项多中心试验。

Quarterly Journal of Medicine Pub Date : 1994-02-01 DOI:10.1093/OXFORDJOURNALS.QJMED.A068903

Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson

{"title":"脂质体两性霉素B (AmBisome)在地中海内脏利什曼病:一项多中心试验。","authors":"Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson","doi":"10.1093/OXFORDJOURNALS.QJMED.A068903","DOIUrl":null,"url":null,"abstract":"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.","PeriodicalId":54520,"journal":{"name":"Quarterly Journal of Medicine","volume":"87 2 1","pages":"75-81"},"PeriodicalIF":0.0000,"publicationDate":"1994-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/OXFORDJOURNALS.QJMED.A068903","citationCount":"188","resultStr":"{\"title\":\"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.\",\"authors\":\"Robert N. Davidson, L. D. Martino, L. Gradoni, Raffaella Giacchino, R. Russo, Giovanni Battista Gaeta, R. Pempinello, S. Scott, Francesco Raimondi, Antonio Cascio, Tullio Prestileo, L. Caldeira, Robert J. Wilkinson, A. Bryceson\",\"doi\":\"10.1093/OXFORDJOURNALS.QJMED.A068903\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.\",\"PeriodicalId\":54520,\"journal\":{\"name\":\"Quarterly Journal of Medicine\",\"volume\":\"87 2 1\",\"pages\":\"75-81\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/OXFORDJOURNALS.QJMED.A068903\",\"citationCount\":\"188\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Quarterly Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A068903\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quarterly Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A068903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 188

摘要

在一项多中心研究中，31例由婴儿利什曼原虫引起的内脏利什曼病(VL)患者接受了两性霉素B脂质体治疗。10例免疫功能正常的患者(6例儿童)接受1 ~ 1.38 mg/kg/天治疗，连续21天;10例(9例儿童)接受3mg /kg/天治疗，连续10天。随访12-24个月，全部治愈，无明显不良反应，无复发。11名免疫功能低下的成年人，包括7名合并感染艾滋病毒(4名合并艾滋病)，每天服用100毫克(1.38-1.85毫克/公斤)，持续21天。所有患者最初都被认为治愈，但其中8人在3-22个月时临床和寄生虫学复发。两性霉素B脂质体是一种安全有效的治疗VL的新药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.

Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Quarterly Journal of Medicine

自引率

0.00%

发文量

期刊最新文献

Analysis of RNA translation with a deep learning architecture provides new insight into translation control. Aortic dissection. Spontaneous periodic hypothermia Unexplained cyanosis caused by hepatopulmonary syndrome in a girl with APECED syndrome. Predicting operative mortality after coronary artery bypass surgery in males.